The Therapeutic Effect And Mechanism Of Dl-3-N-Butylphthalide In Alzheimer'S Disease

Objective: To investigate the efficacy and mechanism of dl-3-n-butylphthalide in the treatment of Alzheimer's disease. Methods: Ninety-six patients with Alzheimer's disease were randomly divided into a conventional treatment group and a dl-3-n-butylphthalide group. Cognitive function evaluations were performed before and after the treatment in the two groups using the Alzheimer's Disease Assessment Scale-Cognitive section, and the patients' serum beta-amyloid protein, IL-1 beta, IL-6 and TNF-alpha levels were quantified using Elisa. Thirty APP/PS1 transgenic mice were randomized into the control group and the dl-3-n-butylphthalide group, and expressions of BDNF and TrkB in the mice's brain tissues were determined using Western blot. Results: At the end of the treatment period, the cognitive function scores and the serum beta-amyloid protein levels of the patients in the dl-3-n-butylphthalide group were significantly lower compared with the conventional treatment group (t=5.210, P=0.000; t=4.816, P=0.000). The serum IL-1 beta and TNF-alpha levels were significantly reduced, but there was no significant difference in IL-6 (t=2.441, P=0.017; t=2.271, P=0.026; t=0.569, P=0.571). Compared with the control group, the BDNF and TrkB expression levels in the mice's brain tissues in the dl-3-n-butylphthalide group were significantly increased (t=18.070, P=0.000; t=12.690, P=0.000). Conclusion: dl-3-n-butylphthalide activates the BDNF-TrkB signaling pathway and therefore plays a therapeutic role in Alzheimer's disease.